Biogen Inc (BIIB) : Lgt Capital Partners Ltd. scooped up 25,150 additional shares in Biogen Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 11, 2016. The investment management firm now holds a total of 84,230 shares of Biogen Inc which is valued at $21,157,734.Biogen Inc makes up approximately 3.59% of Lgt Capital Partners Ltd.’s portfolio.
Other Hedge Funds, Including , Quotient Investors boosted its stake in BIIB in the latest quarter, The investment management firm added 715 additional shares and now holds a total of 8,714 shares of Biogen Inc which is valued at $2,188,870. Biogen Inc makes up approx 1.00% of Quotient Investors’s portfolio. Rosenbaum Jay D. added BIIB to its portfolio by purchasing 1,039 company shares during the most recent quarter which is valued at $261,101. Biogen Inc makes up approx 0.04% of Rosenbaum Jay D.’s portfolio.Curian Capital reduced its stake in BIIB by selling 14,470 shares or 64.62% in the most recent quarter. The Hedge Fund company now holds 7,921 shares of BIIB which is valued at $1,990,547. Biogen Inc makes up approx 0.14% of Curian Capital’s portfolio.Boltwood Capital Management boosted its stake in BIIB in the latest quarter, The investment management firm added 125 additional shares and now holds a total of 2,045 shares of Biogen Inc which is valued at $494,951. Biogen Inc makes up approx 0.41% of Boltwood Capital Management’s portfolio.
Biogen Inc closed down -2.17 points or -0.86% at $251.19 with 12,85,359 shares getting traded on Wednesday. Post opening the session at $254.24, the shares hit an intraday low of $250.82 and an intraday high of $254.27 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Biogen Inc reported $4.79 EPS for the quarter, beating the analyst consensus estimate by $ 0.32 according to the earnings call on Apr 21, 2016. Analyst had a consensus of $4.47. The company had revenue of $2727.00 million for the quarter, compared to analysts expectations of $2745.21 million. The company’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.82 EPS.
Many Wall Street Analysts have commented on Biogen Inc. Biogen Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016. Biogen Inc was Downgraded by Citigroup to ” Neutral” on Jun 7, 2016.
Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.